IDiyas

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Mitsunori Kato

LinkedIn
USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 10.9

ph-index = 5

Forward Citations = 60(Granted Patents)


Location History:

  • Cambridge, MA (US) (2012 - 2021)
  • Long Island, NY (US) (2022 - 2024)

Company Filing History:

goldMedal16 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2012-2025

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 12209098 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2025-01-28),
2. 11952386 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2024-04-09),
3. 11401259 - 1-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2022-08-02),
4. 10975080 - Compounds and compositions for inhibiting the activity of SHP2 (2021-04-13),
5. 10968235 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2021-04-06),
6. 10774065 - 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2020-09-15),
7. 10550102 - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators (2020-02-04),
8. 10336774 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2019-07-02),
9. 10301278 - 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 (2019-05-28),
10. 10208018 - Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators (2019-02-19),
11. 10093646 - 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 (2018-10-09),
12. 10077276 - N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 (2018-09-18),
13. 9957254 - Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators (2018-05-01),
14. 9815813 - 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2 (2017-11-14),
15. 9765067 - Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators (2017-09-19),

Title: Innovations of Mitsunori Kato

Introduction

Mitsunori Kato is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of pharmaceutical sciences. With a total of 16 patents to his name, Kato has made remarkable strides in developing innovative compounds that have the potential to impact various therapeutic areas.

Latest Patents

Among his latest patents, Kato has developed N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2. This invention relates to compounds of formula I, which are designed to provide new avenues for therapeutic intervention.

Career Highlights

Kato's career is marked by his association with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on cutting-edge research and development, contributing to the advancement of medical science.

Collaborations

Throughout his career, Kato has collaborated with notable colleagues, including Zhuoliang Chen and Jorge Garcia Fortanet. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Mitsunori Kato's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key innovator. His work continues to pave the way for future advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…